Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
Researchers identified two distinct cellular communities driving Alzheimer's disease, with one community promoting cognitive decline and the other contributing to the preservation of brain function. The study provides new insights into the molecular mechanisms underlying Alzheimer's, highlighting potential targets for intervention.
Researchers have made progress in understanding how genetics and lifestyle factors influence dementia risk through epigenetics. DNA methylation signatures in blood can mirror protein biomarker levels in spinal fluid samples, used for diagnosing dementia.
Researchers at Boston University created an AI tool that can determine the cause of dementia using commonly collected patient data, boosting doctor accuracy by 26%. The algorithm identifies 10 types of dementia, including vascular and frontotemporal dementia, to help doctors manage patients more effectively.
A new study published in Neurology found that acute kidney injury is associated with an increased risk of developing dementia. The study analyzed data from over 300,000 individuals and found a 49% higher risk of dementia overall, with significant increases for specific types of dementia such as Lewy body dementia and vascular dementia.
Researchers discovered that amyloid fibrils can harness quantum superradiant effects to mitigate oxidative stress, potentially transforming dementia treatments and understanding of Alzheimer's disease. This finding raises questions about the conventional view of amyloid's role in the disease.
A new study from Washington University School of Medicine found that people with multiple sclerosis are less likely to develop the molecular hallmarks of Alzheimer's disease. The discovery suggests a potential new avenue for treating Alzheimer's and could inform therapeutic strategies.
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
Researchers at Penn State and Stanford University discovered that blocking IDO1 enzyme can rescue memory and brain function in models of Alzheimer's disease. This breakthrough suggests that IDO1 inhibitors, already developed for cancer treatment, could be used to treat early stages of neurodegenerative diseases.
A team of neuroscientists at Stanford University discovered that blocking the kynurenine pathway can improve cognitive function in lab mice with Alzheimer’s disease. The study found that drugs that block this pathway improved glucose metabolism, corrected astrocytic performance, and enhanced spatial memory in the mice.
Researchers from UC Irvine have discovered the neurons responsible for item memory, a crucial component of cognitive function. The study sheds light on how the brain stores and retrieves memories, particularly in relation to rewards or punishments.
Scientists at IOCB Prague have developed a new compound that suppresses appetite and protects the brain against Alzheimer's disease. The modified molecule, derived from the neuropeptide CART, is effective in reducing pathology associated with Alzheimer's.
A new study found Black Americans have a higher risk of developing Alzheimer's disease and face greater treatment burdens due to lack of awareness. Researchers propose strategies to support brain health in this community, including increasing education on activities that promote healthy aging.
A Boston University researcher is testing whether neurofeedback can improve memory consolidation in patients with early-stage Alzheimer's disease. The study aims to amplify theta oscillatory brain activity during waking rest to boost memory in both healthy older adults and those with the condition.
Researchers tested lecanemab, an anti-amyloid drug, on brain tissue samples from individuals with Down syndrome, finding it effectively targeted amyloid plaques but also bound to blood vessels. The study highlights the need for careful consideration of safety and potential hemorrhagic complications in people with Down syndrome.
A new national study reveals significant regional variations in the likelihood of being diagnosed with Alzheimer's disease or another form of dementia. Despite controlling for demographic and population-level risk factors, the study found that differences in diagnostic intensity persist across regions.
Researchers successfully restored the brain's waste-clearing process by reviving cervical lymph vessel function in aging mice, utilizing a known drug to boost efficiency. This breakthrough could pave the way for future therapies targeting neurodegenerative diseases.
Researchers at Edith Cowan University have uncovered a significant genetic connection between Alzheimer's disease and several coronary artery disease-related disorders, offering opportunities to improve health outcomes. The study found that some of the same genes played a role in or are associated across these conditions.
Researchers have developed a protein drug that can suppress the effects of harmful amyloid beta biomolecule, indicating potential for halting disease progression. The therapy targets neuronal dysfunctions and shows encouraging results in animal experiments.
A meta-analysis of 31,250 people found that those with untreated high blood pressure had a 36% increased risk of Alzheimer's disease compared to those without the condition. Taking blood pressure medication was associated with decreased risk of Alzheimer's disease throughout later life.
A study found that older age, female sex, and irregular heart rhythms can predict Alzheimer's cognitive decline over two years. The results also showed strong correlations between caregiver load and various patient-related measures.
A study at the University of Helsinki discovered a new type of degenerative brain disease, limbic-predominant age-related TDP-43 encephalopathy (LATE), prevalent among the oldest old. LATE is associated with similar symptoms to early Alzheimer's but progresses more slowly and is milder.
Glial cells play a significant role in Alzheimer's disease, producing amyloid beta and contributing to plaque formation. Researchers discovered that knocking out BACE1 enzyme in oligodendrocytes reduced plaque formation by 30%, opening up new avenues for therapies.
A team led by Emory researchers found strong evidence supporting a new understanding of the mechanism behind Alzheimer's disease. They identified more than 20 proteins that co-accumulate with amyloid beta, suggesting they may play an important role in brain damage rather than the amyloid itself.
A new USC study led by Caleb Finch shows how feeding mice the drug GSM-15606 provided protection against air pollution-related increases in proteins linked to Alzheimer's disease. The results indicate that GSM-15606 may one day have a role as a preventive measure against Alzheimer's in people living with air pollution.
A new study by Umeå University found that people with type 2 diabetes have difficulty eliminating beta-amyloids, which may contribute to Alzheimer's disease. The researchers suggest that preventing or managing type 2 diabetes could reduce the risk of cognitive decline.
A new $3.5 million NIH grant will investigate the complex interplay between traumatic brain injury and genetic risk factors in the development of Alzheimer's disease. The three-year study will use rodents to assess disease progression across different age periods, providing insights into potential early intervention strategies.
A UCLA researcher identified a compound that effectively jumpstarts the brain's memory circuitry, restoring cognitive functions in mice with Alzheimer's disease symptoms. The molecule, DDL-920, works by targeting specific neurons to enhance gamma oscillations, which are critical for memory and cognition.
A study published in Science Advances found that the quality of synapses, specifically dendritic spine head diameter, predicts episodic memory performance in older adults. Researchers suggest targeting pathways that maintain spine head diameter or synaptic strength may yield greater therapeutic benefits for Alzheimer's disease prevention.
Researchers found that dopamine treatment increased neprilysin levels and reduced beta-amyloid plaques in mouse brains, improving memory function. Long-term L-DOPA treatment also showed improved cognitive performance in mice.
Researchers question the effectiveness of new amyloid immunotherapy drugs in reducing Alzheimer's disease impact, citing limited eligibility and high costs. The drugs showed small effect sizes that may not outweigh the risk of adverse events.
A UC Irvine-led team discovered how the TREM2 R47H genetic mutation causes abnormal protein clumps in brain areas associated with late-onset Alzheimer's disease. The study provides first-of-their-kind insights into the effects of the mutation on gene expression and cellular functions.
Maintaining stable hemoglobin A1c levels in individualized target ranges may lower Alzheimer disease and related dementias risk. Lower HbA1c time in range could identify patients at increased risk of these conditions.
Researchers used long-read sequencing to map out gene isoform diversity in the brains of mice with human tau protein mutations. The study found hundreds of new isoforms associated with tau accumulation and differential expression in human Alzheimer's disease tissue.
A clinical trial found that fish oil supplements slowed neuronal integrity breakdown in older adults with the APOE4 gene variant, a risk factor for Alzheimer's disease. The study showed no benefit for all older adults, but suggested omega-3 fatty acids may be useful for prevention.
Researchers developed a method to study aged neurons in the lab without a brain biopsy, revealing aspects of cells' genomes linked to late-onset Alzheimer's development. The technique suggests new treatment strategies targeting retrotransposable elements and early intervention to slow disease progression.
Researchers developed a method to study aged neurons in the lab without a brain biopsy, accurately reproducing the hallmarks of late-onset Alzheimer's disease. The study identified aspects of cells' genomes that contribute to the development of the disease and found potential treatment strategies targeting these factors.
Scientists create fluorescent sensors that can detect neurotransmitter levels in the brain, allowing for non-invasive live brain imaging. The technology has shown promise for advancing Alzheimer's disease diagnosis and treatment.
Researchers at Mayo Clinic used AI to analyze electroencephalogram (EEG) tests, identifying subtle brain wave patterns characteristic of cognitive problems like Alzheimer's disease. This technology has the potential to provide healthcare professionals with a more accessible tool for early diagnosis in communities without easy access to...
Researchers discovered elevated levels of neurofilament light chain protein in Parkinson's disease and dementia with Lewy bodies, suggesting potential early detection methods. The study found different protein patterns between the prodromal stage and established diseases.
Researchers have identified the critical step in NMDAR's routine where it rotates into an open formation, enabling electrical signals crucial for cognitive functions. This discovery may pave the way for drug compounds that can correct faulty NMDARs, potentially treating conditions like Alzheimer's and depression.
A new study suggests that public health interventions, such as reformulating food products and introducing low emission zones, could yield significant cost savings and QALY gains in England. The interventions studied could save up to £4bn by reducing dementia rates and helping people live longer and healthier.
Researchers used advanced imaging techniques to create detailed maps of mouse brains, identifying areas vulnerable to blood vessel degeneration. These changes can lead to cognitive decline and neurodegenerative disorders like Alzheimer's disease.
A head-to-head comparison of six commercial blood tests found that some are accurate enough to replace spinal taps and brain scans in patients with cognitive impairment. The analysis, led by Suzanne Schindler at Washington University School of Medicine, identified reliable tests for diagnosing Alzheimer's disease.
A novel study finds that monitoring cortical microstructural change in the brain using diffusion weighted MRI scans may help identify individuals at risk for cognitive decline and Alzheimer's disease. Tracking these changes over time could provide precious time for disease-modifying treatments.
Viji Santhakumar, a UCR professor, has been awarded a $3.5 million NIH grant to study brain circuit function and its impact on memory formation and cognitive deficits in diseases like epilepsy and Alzheimer's disease.
Researchers found high diagnostic accuracy for identifying Alzheimer's disease using amyloid probability score 2 blood test and p-tau217 levels. The study suggests blood tests could influence clinical care, warranting further evaluation.
Researchers studied Alzheimer disease blood biomarkers and found a strong association with incident all-cause dementia risk. Biomarker levels increased with age and were linked to dementia starting in midlife.
A new study found that early-onset dementia is more common than previously reported, with the incidence of Alzheimer's disease increasing by nearly double in the working-age population. The study analyzed patient data from Finland and found higher incidence rates of early-onset dementia compared to previous international studies.
A new study reveals that traffic-related ultrafine particles hinder mitochondrial functions in human olfactory mucosa cells, impairing oxidative phosphorylation and redox balance. Individuals with Alzheimer's disease showed altered responses to UFP exposure.
Scientists at the Jackson Laboratory created a mouse model for late-onset Alzheimer’s disease by introducing genetic variants associated with the illness into mice. They used transcriptomics to analyze brain tissue and identify key biological signatures, paving the way for testing new therapeutics.
A study by USTC researchers has identified a unique type of neutrophil significantly associated with Alzheimer's disease pathology. The analysis reveals six distinct neutrophil clusters, with the Neu-5 cluster displaying unique characteristics and an altered inflammatory response.
A new study reveals specific brain regions and cell types that are vulnerable to Alzheimer's disease, while others show resilience. Gene expression analysis and lab experiments highlight the role of Reelin in neuronal vulnerability and choline/antioxidants in sustaining cognition.
Scientists successfully mapped transcriptomes from 1.3 million brain cortex cells to gain molecular insights into Alzheimer's vulnerability and resilience. The resulting atlas holds promise for gene and molecular discovery across pathways affecting brain health.
A team of researchers has developed a comprehensive ranking of genes and proteins involved in Alzheimer's disease, providing a roadmap for more targeted research and drug discovery. The study integrates findings from multiple fields and identifies thousands of potential therapeutic targets.
Oligodendrocyte-derived amyloid beta produces toxic peptide that promotes neuronal dysfunction in Alzheimer's disease. Selective suppression of oligodendrocyte Aβ production rescues abnormal neuronal hyperactivity, suggesting targeting these cells as a promising therapeutic strategy for AD.
The A4 study, a large clinical trial of pre-symptomatic Alzheimer’s disease, has yielded key insights into the condition. Researchers have collected extensive data on brain scans, blood samples, genetic information and cognitive tests from over 7,500 participants.
Mayo Clinic scientists have established criteria for a memory-loss syndrome in older adults that specifically impacts the brain's limbic system. The syndrome, called Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), progresses more slowly and has a better prognosis than Alzheimer's disease.
A new study from Boston University Chobanian & Avedisian School of Medicine found a link between AD pathology and emotional behavioral symptoms. Individuals with AD who decline in memory abilities also experience worsened mental health, which may be due to underlying brain changes.
Researchers at Rice University found that chronic stress impacts cellular health, leading to decreased energy levels and increased inflammation, which can result in dementia, Alzheimer's disease, and other health problems. Caregivers with less leftover cellular energy experience fewer positive emotions and have lower physical functioning.